{"schema_version":"1","generated_at":"2026-10-29T01:15:53.457Z","data_as_of":"2026-10-23","url":"https://www.findmykol.com/kol/margaret-kasner","json_url":"https://www.findmykol.com/kol/margaret-kasner/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"margaret-kasner","name":"Margaret Kasner","credential":"MD","title":"Professor, Medical Oncology","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Leukemia","therapeutic_areas":["Leukemia"],"institution":"Thomas Jefferson University","institution_url":"https://www.findmykol.com/institution/thomas-jefferson-university","city":"Philadelphia","state":"PA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1194885251","orcid":"0000-0001-8616-744X","openalex":"A5082967415"},"summary":"Margaret Kasner is Professor, Medical Oncology at Thomas Jefferson University. OpenAlex indexes 144 publications with 2,542 citations (h-index 19); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.","overview":{"text":"Margaret T. Kasner, M.D., is Professor, Medical Oncology at Thomas Jefferson University (Sidney Kimmel Comprehensive Cancer Center). The public record shows 144 publications with 2,542 citations (h-index 19), centered on Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Retinoids in leukemia and cellular processes. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 11 companies, 1 NIH-funded awards (2020–2022).","bullets":["Most recent indexed publication: 2026 · Cancers","Top research focus: Acute Myeloid Leukemia Research","8 registered trials on ClinicalTrials.gov","Open Payments reporting from 11 companies"],"generated_at":"2026-10-28"},"focus":{"indications":[{"label":"Leukemia (AML/ALL/CML/CLL)","therapeutic_area":"Oncology","trials":7,"topics":1,"strength":22},{"label":"Leukemia, Myeloid, Acute","therapeutic_area":"Oncology","trials":5,"topics":0,"strength":15},{"label":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"MDS / MPN","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Lymphoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Recurrence","therapeutic_area":"Epidemiology","trials":1,"topics":0,"strength":3},{"label":"Burkitt Lymphoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Leukemia, T-Cell","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Leukemia, Erythroblastic, Acute","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Acute Myeloid Leukemia Research","Hematopoietic Stem Cell Transplantation","Retinoids in leukemia and cellular processes","Transplantation: Methods and Outcomes","Renal Transplantation Outcomes and Treatments"],"drugs_studied":{"total":12,"shown":3,"withheld":9,"rows":[{"name":"Venclexta","generic":"Venetoclax","trials":0,"payments":7,"publications":1,"mentions":8},{"name":"Rytelo","generic":"Imetelstat","trials":0,"payments":4,"publications":0,"mentions":4},{"name":"Tibsovo","generic":"Ivosidenib","trials":0,"payments":4,"publications":0,"mentions":4}]},"works_with":{"total":13,"shown":3,"withheld":10,"rows":[{"name":"Genentech, Inc.","trials":0,"payments":7,"mentions":7},{"name":"Servier Pharmaceuticals LLC","trials":0,"payments":7,"mentions":7},{"name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","trials":7,"payments":0,"mentions":7}]}},"scholarship":{"works_count":144,"cited_by_count":2542,"h_index":19,"i10_index":25,"pubmed_count":4,"latest_activity_year":2026,"source":"works"},"trials":{"count":8,"shown":3,"withheld":5,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT05564390","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","phase":"PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT05564390","trial_url":"https://www.findmykol.com/trial/NCT05564390"},{"nct":"NCT03472573","title":"Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia","phase":"PHASE1","status":"COMPLETED","role":"Investigator","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","source_url":"https://clinicaltrials.gov/study/NCT03472573","trial_url":"https://www.findmykol.com/trial/NCT03472573"},{"nct":"NCT03063944","title":"STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy","phase":"PHASE1","status":"COMPLETED","role":"Investigator","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","source_url":"https://clinicaltrials.gov/study/NCT03063944","trial_url":"https://www.findmykol.com/trial/NCT03063944"}],"source":"trials"},"payments":{"company_count":11,"program_years":{"first":2021,"last":2025},"rows_total":15,"shown":3,"withheld":12,"rows":[{"payer":"Geron Corporation","program_year":2025,"amount_usd":4858.83,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1194885251"},{"payer":"Daiichi Sankyo Inc.","program_year":2025,"amount_usd":4151.27,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1194885251"},{"payer":"Janssen Research & Development, LLC","program_year":2025,"amount_usd":2271.09,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1194885251"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1194885251","source":"payments"},"funding":{"award_count":1,"fiscal_years":{"first":2020,"last":2022},"rows_total":4,"shown":3,"withheld":1,"rows":[{"project":"P30CA056036","title":"Protocol Review and Monitoring System","fiscal_year":2022,"amount_usd":78141,"organization":"THOMAS JEFFERSON UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/P30CA056036"},{"project":"P30CA056036","title":"Protocol Review and Monitoring System","fiscal_year":2021,"amount_usd":78141,"organization":"THOMAS JEFFERSON UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/P30CA056036"},{"project":"P30CA056036","title":"Protocol Review and Monitoring System","fiscal_year":2020,"amount_usd":391000,"organization":"THOMAS JEFFERSON UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/P30CA056036"}],"source":"grants"},"congress":{"count":30,"years":{"first":2017,"last":2025},"societies":["AACR","ASCO","ASH","ASTRO"],"shown":3,"withheld":27,"rows":[{"title":"Results of part 1 of a two-part study evaluating the combination of tazemetostat and CPX-351 (part 1) and palbociclib with CPX-351 (part 2) for the treatment of relapsed or refractory Acute Myeloid Leukemia","society":"ASH","meeting":"ASH Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1182/blood-2025-1686","source_url":"https://doi.org/10.1182/blood-2025-1686","status":"verified"},{"title":"Safety evaluation for less restrictive discharge criteria for patients receiving high dose methotrexate","society":"ASH","meeting":"ASH Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1182/blood-2025-521","source_url":"https://doi.org/10.1182/blood-2025-521","status":"verified"},{"title":"Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study","society":"ASH","meeting":"ASH Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1182/blood-2025-654","source_url":"https://doi.org/10.1182/blood-2025-654","status":"verified"}],"source":"congress"},"publications":{"total":4,"shown":4,"withheld":0,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Management of Acute Myeloid Leukemia: A Review.","year":2026,"journal":"Cancers","types":["Journal Article","Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41749912/","status":"verified"},{"title":"Targeting CD47: many misses; hopeful for a hit.","year":2025,"journal":"Blood","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/39883445/","status":"verified"},{"title":"North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic Era.","year":2024,"journal":"JCO oncology practice","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/38950320/","status":"verified"},{"title":"A Phase I Trial of Sirolimus with \"7&3\" Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia.","year":2023,"journal":"Cancers","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/37958304/","status":"verified"}],"most_cited":{"total":144,"shown":5,"withheld":139,"rows":[{"title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML","year":2019,"cited_by_count":1282,"type":"article","source_url":"https://doi.org/10.1056/nejmoa1902688"},{"title":"The diabetes gene Pdx1 regulates the transcriptional network of pancreatic endocrine progenitor cells in mice","year":2009,"cited_by_count":177,"type":"article","source_url":"https://doi.org/10.1172/jci37028"},{"title":"A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia","year":2009,"cited_by_count":105,"type":"article","source_url":"https://doi.org/10.1158/1078-0432.ccr-09-0842"},{"title":"Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts","year":2016,"cited_by_count":90,"type":"article","source_url":"https://doi.org/10.3324/haematol.2015.139717"},{"title":"Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)","year":2014,"cited_by_count":76,"type":"article","source_url":"https://doi.org/10.1182/blood.v124.21.116.116"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"John L. Wagner","coauthored_works":50},{"name":"Neal Flomenberg","coauthored_works":50,"profile_url":"https://www.findmykol.com/kol/neal-flomenberg"},{"name":"Önder Alpdoğan","coauthored_works":47}],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/margaret-kasner-md","status":"provisional"}]},"mentions":{"total":2,"shown":2,"rows":[{"url":"https://binaytara.org/projects/conferences/speakers/margaret-kasner","platform":"other","status":"provisional"},{"url":"https://jefferson.edu/academics/colleges-schools-institutes/skmc/departments/medical-oncology/faculty/kasner.html","platform":"other","status":"provisional"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":6,"shown":6,"rows":[{"value":"Medical School: University of Pennsylvania School of Medicine (2001)","source_url":"http://www.jefferson.edu/academics/colleges-schools-institutes/skmc/departments/medical-oncology/faculty/kasner.html","status":"verified","collected_at":"2026-10-28"},{"value":"MD (NPI-registry credential corroborated)","source_url":"http://www.jefferson.edu/academics/colleges-schools-institutes/skmc/departments/medical-oncology/faculty/kasner.html","status":"verified","collected_at":"2026-10-28"},{"value":"MSCE (master's degree)","source_url":"http://www.jefferson.edu/academics/colleges-schools-institutes/skmc/departments/medical-oncology/faculty/kasner.html","status":"verified","collected_at":"2026-10-28"},{"value":"Board certified: Medical Oncology","source_url":"http://www.jefferson.edu/academics/colleges-schools-institutes/skmc/departments/medical-oncology/faculty/kasner.html","status":"provisional","collected_at":"2026-10-28"},{"value":"Board certified: Internal Medicine","source_url":"http://www.jefferson.edu/academics/colleges-schools-institutes/skmc/departments/medical-oncology/faculty/kasner.html","status":"provisional","collected_at":"2026-10-28"},{"value":"Board certified: Hematology","source_url":"http://www.jefferson.edu/academics/colleges-schools-institutes/skmc/departments/medical-oncology/faculty/kasner.html","status":"provisional","collected_at":"2026-10-28"}]},"roles":{"total":4,"shown":3,"rows":[{"value":"Director, Leukemia Group","source_url":"http://www.jefferson.edu/academics/colleges-schools-institutes/skmc/departments/medical-oncology/faculty/kasner.html","status":"verified","collected_at":"2026-10-28"},{"value":"Director, Division of Hematologic Malignancies","source_url":"http://www.jefferson.edu/academics/colleges-schools-institutes/skmc/departments/medical-oncology/faculty/kasner.html","status":"verified","collected_at":"2026-10-28"},{"value":"Associate Director, Clinical Research, Sidney Kimmel Comprehensive Cancer Center","source_url":"http://www.jefferson.edu/academics/colleges-schools-institutes/skmc/departments/medical-oncology/faculty/kasner.html","status":"verified","collected_at":"2026-10-28"}]},"media":{"total":1,"shown":1,"rows":[{"value":"HealthTree podcast: Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner","source_url":"https://healthtree.org/aml/podcasts/targeting-flt3-positive-aml-with-new---improved-therapies-2","status":"provisional","collected_at":"2026-10-28"}]}},"similar":[{"name":"David Whellan","slug":"david-whellan","institution":"Thomas Jefferson University","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/david-whellan","json_url":"https://www.findmykol.com/kol/david-whellan/profile.json"},{"name":"Jesse Roman","slug":"jesse-roman","institution":"Thomas Jefferson University","specialty":"Pulmonary Disease","url":"https://www.findmykol.com/kol/jesse-roman","json_url":"https://www.findmykol.com/kol/jesse-roman/profile.json"},{"name":"Wenyin Shi","slug":"wenyin-shi","institution":"Thomas Jefferson University","specialty":"Radiation Oncology","url":"https://www.findmykol.com/kol/wenyin-shi","json_url":"https://www.findmykol.com/kol/wenyin-shi/profile.json"},{"name":"Stephen Silberstein","slug":"stephen-silberstein","institution":"Thomas Jefferson University","specialty":"Neurology","url":"https://www.findmykol.com/kol/stephen-silberstein","json_url":"https://www.findmykol.com/kol/stephen-silberstein/profile.json"},{"name":"Hagop Kantarjian","slug":"hagop-kantarjian","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/hagop-kantarjian","json_url":"https://www.findmykol.com/kol/hagop-kantarjian/profile.json"},{"name":"Jorge Cortes","slug":"jorge-cortes","institution":"University of Alabama at Birmingham (UAB)","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/jorge-cortes","json_url":"https://www.findmykol.com/kol/jorge-cortes/profile.json"},{"name":"Ayalew Tefferi","slug":"ayalew-tefferi","institution":"Mayo Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/ayalew-tefferi","json_url":"https://www.findmykol.com/kol/ayalew-tefferi/profile.json"},{"name":"Charles Sawyers","slug":"charles-sawyers","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/charles-sawyers","json_url":"https://www.findmykol.com/kol/charles-sawyers/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":5,"payments":12,"funding":1,"congress":27,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-28"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-28"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-10-28"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-10-28"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-10-28"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-28"}},"methodology_url":"https://www.findmykol.com/about#methodology"}